The New Drugs Targeting Human Metabolism

Walk into a pharmacy in almost any major city right now and you’ll notice something that would have seemed unlikely five years ago: the most talked-about drug section isn’t pain relief or antibiotics. It’s the metabolic aisle, dominated by GLP-1 receptor agonists — Ozempic, Mounjaro, Wegovy — medicines that have crossed the threshold from clinical tool into genuine cultural phenomenon.

The waiting lists are long. The social media content is relentless. And the market is worth over $53 billion annually, heading toward $156 billion by 2030 according to Grand View Research. By almost any commercial measure, the GLP-1 era is going extremely well.

And yet, roughly half of patients with difficult-to-manage diabetes remain poorly controlled. Cardiovascular disease, often driven by metabolic syndrome, is still the leading cause of death in the United States. People sit in endocrinology offices having tried everything on the approved list and still aren’t getting where they need to be. There’s a real frustration in those rooms — a sense, as Sparrow Pharma’s CEO Robert Jacks put it recently, of swimming upstream against an invisible current, blamed for poor compliance when in fact something biological is quietly working against them.

That’s the gap two very different companies are now trying to fill, using approaches that look nothing like the injections dominating the space today.

Aphaia Pharma, based in Switzerland, has spent years developing an oral glucose formulation — tiny beads and a powder that forms a hydrogel when mixed with water — designed to reach the lower part of the small intestine, a section of the gut that most food never actually gets to. The reason, according to Aphaia’s chief scientific officer Steffen-Sebastian Bolz, is not complicated: modern diets are too heavy in proteins and fats, which slow the passage of the food bolus and prevent nutrients from reaching the distal intestine where nutrient-sensing cells sit, pre-loaded with hormones and waiting for a signal that rarely comes.

“It’s like lighting a Christmas tree,” Bolz said. “You put in one plug, and the whole thing lights up.” What Aphaia’s beads do, bypassing the food bolus by traveling along the intestinal wall, is essentially send that plug in artificially, triggering a cascade of hormone releases — GLP-1, GLP-2, insulin, and several others — that the body already knows how to produce. Not a shot. No synthetic hormone would be produced if it were injected into the bloodstream at concentrations greater than those found in a typical meal. Just a water-washed oral formulation that instructs the current infrastructure to perform its function.

The medication, known as APHD-012, has passed two Phase 2 trials in patients with obesity complicated by liver disease and pre-diabetes. Over the course of six weeks, it improved glucose tolerance in pre-diabetic patients by achieving targeted release in the distal small intestine, whereas a placebo had no similar effect.

The response duration, Bolz noted, is actually longer than a normal meal because of the way the beads are designed — producing a larger total hormone release without ever spiking above physiologically normal levels, which is why, they argue, the side effect profile looks so much cleaner than a GLP-1 injection. It’s not too late yet. The trial sizes are small. However, the idea of utilizing the body’s own cellular machinery instead of overpowering it is actually intriguing and more difficult to reject than it might first seem.

Sparrow Pharma is pursuing an entirely distinct issue. Its lead drug, clofutriben, blocks an enzyme called HSD1, which inside cells converts the inactive form of cortisol — cortisone — back into active cortisol. For patients whose metabolic dysfunction is being driven by chronically elevated cortisol levels, often without their awareness or their doctor’s, standard diabetes and obesity treatments simply don’t work well.

The GLP-1 might be doing its part, but cortisol keeps pushing back, raising blood sugar, driving fat accumulation, and generating insulin resistance. According to Jacks, these patients unintentionally have a biological anchor. Research suggests that nearly half of patients with hard-to-control diabetes have elevated cortisol as an underlying factor — a number that’s easy to underestimate given how rarely it’s tested for.

Clofutriben has already received Orphan Drug Designation from the FDA, and a Phase 2 study specifically focused on cortisol-linked Type 2 diabetes will be funded by Sparrow’s recent $95 million Series B. Although Phase 2 results could still surprise in either direction, that is a significant vote of confidence.

Meanwhile, at the University of Glasgow, researchers have mapped the atomic-level structure of FFA2 — a receptor activated by short-chain fatty acids produced when gut bacteria ferment dietary fiber — finding that different synthetic activators each interact with the receptor in distinct ways, opening the possibility of tuning the response to improve pancreatic function, immune cell behavior, or fat storage control depending on what a particular patient needs.

The pancreas, fat tissue, and immune cells all contain the receptor. Although it’s still mostly theoretical at this point, precisely targeting it might eventually enable something like customized metabolic therapy.

It’s difficult to ignore how much of this work revolves around the same fundamental realization: the body already possesses the majority of the necessary mechanisms. How to replace them is not the question. It’s how to get in touch with them.